Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Lifted to Hold at Zacks Investment Research

Share on StockTwits

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “Swedish Orphan Biovitrum is a biotechnology company. It develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio consists of Core Products segment which offers pharmaceuticals within Inflammation area and Genetics and metabolic therapeutic area; Partner Products segment which offers pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The company operates primarily in Sweden, Denmark, Finland, Norway, United Kingdom and France. Swedish Orphan Biovitrum is based in Solna, Sweden. “

Separately, Deutsche Bank downgraded shares of Swedish Orphan Biovitrum AB (publ) from a “buy” rating to a “hold” rating in a research note on Thursday, July 18th.

Shares of OTCMKTS:BIOVF remained flat at $$16.35 during trading on Tuesday. The company has a fifty day simple moving average of $18.99. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.55 and a current ratio of 0.75. Swedish Orphan Biovitrum AB has a twelve month low of $16.35 and a twelve month high of $21.20.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.

Featured Article: How to invest using market indexes

Get a free copy of the Zacks research report on Swedish Orphan Biovitrum AB (publ) (BIOVF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.